(R)-thionisoxetine, a potent and selective inhibitor of central and peripheral norepinephrine uptake.
Life Sci., 56(22):1915-20 (1995)
Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
J. Pharmacol. Exp. Ther., May;273(2):695-701 (1995)
Comparison of indolidan analog binding sites of drug antibody and sarcoplasmic reticulum with inhibition of cyclic AMP phosphodiesterase.
J. Recept. Signal Transduct. Res., 16(5-6):315-37 (1996)
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
Mol. Pharmacol., Jan;57(1):75-81 (2000)
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
J. Med. Chem., Jan;35(2):310-9 (1992)
mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors.
Life Sci., 50(8):599-605 (1992)
Chiral recognition of pinacidil and its 3-pyridyl isomer by canine cardiac and smooth muscle: antagonism by sulfonylureas.
J. Pharmacol. Exp. Ther., Jan;256(1):222-9 (1991)
Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites.
J. Med. Chem., Jul;32(7):1476-80 (1989)
Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium.
Mol. Pharmacol., Aug;36(2):302-11 (1989)
Depletion of cardiac norepinephrine but not brain catecholamines by MPTP-N-oxide in mice.
Life Sci., 47(9):815-9 (1990)
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
J. Med. Chem., Dec;33(12):3176-81 (1990)
Characterization and pharmacological relevance of high affinity binding sites for [3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes.
Circ. Res., Jul;65(1):154-63 (1989)
Comparative effects of 1-ethyl- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridines on catecholamine concentrations in mouse brain and heart.
Res. Commun. Chem. Pathol. Pharmacol., Jan;59(1):129-32 (1988)
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
J. Med. Chem., Jul;31(7):1290-5 (1988)
Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) effects on mouse heart norepinephrine.
Biochem. Pharmacol., Sep;37(17):3343-7 (1988)
Specific binding of [3H]LY186126, an analogue of indolidan (LY195115), to cardiac membranes enriched in sarcoplasmic reticulum vesicles.
Circ. Res., May;64(5):1037-40 (1989)
Electrophysiological effects of flecainide enantiomers in canine Purkinje fibres.
Naunyn Schmiedebergs Arch. Pharmacol., Jun;339(6):625-9 (1989)
Molecular basis for the in vitro and in vivo cardiotonic activities of AR-L100.
J. Pharmacol. Exp. Ther., Nov;239(2):375-81 (1986)
LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.
Mol. Pharmacol., Dec;30(6):609-16 (1986)
Pharmacology of LY195115, a potent, orally active cardiotonic with a long duration of action.
J. Cardiovasc. Pharmacol., Apr;9(4):425-34 (1987)